← All Sponsors
SPONSOR

Convergent Therapeutics

Total Trials
1
Recruiting
1
Phases
Phase 2
Conditions studied: PSMA PET-Positive Castration-Resistant Prostate Cancer
NCT06549465 Phase 2
Recruiting

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

PSMA PET-Positive Castration-Resistant Prostate Cancer
United States View Trial →